Literature DB >> 15894543

The Jak1 SH2 domain does not fulfill a classical SH2 function in Jak/STAT signaling but plays a structural role for receptor interaction and up-regulation of receptor surface expression.

Simone Radtke1, Serge Haan, Angela Jörissen, Heike M Hermanns, Sandra Diefenbach, Tanya Smyczek, Hildegard Schmitz-Vandeleur, Peter C Heinrich, Iris Behrmann, Claude Haan.   

Abstract

The presence of a Src homology 2 (SH2) domain sequence similarity in the sequence of Janus kinases (Jaks) has been discussed since the first descriptions of these enzymes. We performed an in depth study to determine the function of the Jak1 SH2 domain. We investigated the functionality of the Jak1 SH2 domain by stably reconstituting Jak1-defective human fibrosarcoma cells U4C with endogenous amounts of Jak1 in which the crucial arginine residue Arg466 within the SH2 domain has been replaced by lysine. This mutant still binds to the receptor subunits gp130 and OSMR. Moreover, the SH2 R466K mutation does not affect the subcellular distribution of Jak1 as assessed by cell fractionation and confocal microscopy of cells expressing endogenous levels of non-tagged or a yellow fluorescent protein (YFP)-tagged Jak1-R466K, respectively. Likewise, the signaling capacity of Jak1 was not affected by this point mutation. However, we found that the SH2 domain is structurally important for cytokine receptor binding and surface expression of the OSMR.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15894543     DOI: 10.1074/jbc.M500822200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

Review 1.  Biology and significance of the JAK/STAT signalling pathways.

Authors:  Hiu Kiu; Sandra E Nicholson
Journal:  Growth Factors       Date:  2012-02-20       Impact factor: 2.511

Review 2.  JAK2 inhibitors: what's the true therapeutic potential?

Authors:  Fabio P S Santos; Srdan Verstovsek
Journal:  Blood Rev       Date:  2010-11-20       Impact factor: 8.250

3.  JAK-cytokine receptor recognition, unboxed.

Authors:  Randall McNally; Michael J Eck
Journal:  Nat Struct Mol Biol       Date:  2014-05       Impact factor: 15.369

4.  Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies.

Authors:  Shashidhar S Jatiani; Stacey J Baker; Lewis R Silverman; E Premkumar Reddy
Journal:  Genes Cancer       Date:  2010-10

Review 5.  JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.

Authors:  Lorraine Springuel; Jean-Christophe Renauld; Laurent Knoops
Journal:  Haematologica       Date:  2015-10       Impact factor: 9.941

Review 6.  The use of structural biology in Janus kinase targeted drug discovery.

Authors:  Nilda L Alicea-Velázquez; Titus J Boggon
Journal:  Curr Drug Targets       Date:  2011-04       Impact factor: 3.465

Review 7.  Janus kinases in immune cell signaling.

Authors:  Kamran Ghoreschi; Arian Laurence; John J O'Shea
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

8.  JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors.

Authors:  Alexandra Dusa; Céline Mouton; Christian Pecquet; Murielle Herman; Stefan N Constantinescu
Journal:  PLoS One       Date:  2010-06-16       Impact factor: 3.240

Review 9.  SH2 domains: modulators of nonreceptor tyrosine kinase activity.

Authors:  Panagis Filippakopoulos; Susanne Müller; Stefan Knapp
Journal:  Curr Opin Struct Biol       Date:  2009-11-18       Impact factor: 6.809

10.  Classification of nonenzymatic homologues of protein kinases.

Authors:  K Anamika; K R Abhinandan; K Deshmukh; N Srinivasan
Journal:  Comp Funct Genomics       Date:  2009-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.